Search Results - "EPISTENT Investigators"

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

Authors: Topol EJ Mark DB Lincoff AM et al.

Source: Lancet. 12/11/1999, Vol. 354 Issue 9195, p2019-2024. 6p.

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: EPISTENT Investigators (CORPORATE AUTHOR)

Source: Lancet. 7/11/1998, Vol. 352 Issue 9122, p87-92. 6p.

Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT)

Authors: Islam, M.Ashequl Blankenship, James C. Balog, Craig et al.

Source: American Journal of Cardiology. Nov2002, Vol. 90 Issue 9, p916-921. 6p.

abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile

Authors: Kereiakes, Dean J. Lincoff, A.Michael Anderson, Keaven M. et al.

Source: American Journal of Cardiology. Sep2002, Vol. 90 Issue 6, p628-630. 3p.